Manufacturer
Sanofi-Aventis Deutschland GmbH
Contents
Alirocumab
Indication
Heterozygous familial hypercholesterolaemia, Mixed dyslipidaemia, Nonfamilial hypercholesterolaemia
Instruction
Administer via Subcutaneous.
Drug interaction
Increased target-mediated clearance and reduced systemic plasma concentration with statins and other lipid-lowering agents (e.g. ezetimibe, fenofibrate).
Sanofi-Aventis Deutschland GmbH
Contents
Alirocumab
Indication
Heterozygous familial hypercholesterolaemia, Mixed dyslipidaemia, Nonfamilial hypercholesterolaemia
Instruction
Administer via Subcutaneous.
Drug interaction
Increased target-mediated clearance and reduced systemic plasma concentration with statins and other lipid-lowering agents (e.g. ezetimibe, fenofibrate).
Inquiry - Praluent 150 mg Solution for Injection in Pre-Filled Pen